Keywords: Bayer, Xarelto, Japan, Stroke, Systemic embolism, Regorafenib, Onyx Pharma, Colorectal cancer

Bayer’s Xarelto OKed in Japan; promising regorafenib data

Article | 19 January 2012

Print This

Bayer Healthcare, a unit of Germany’s Bayer AG (BAY: DE), had a couple of good news item to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in